Access To Drugs and Intellectual Property Rights Clash In Case With Worldwide Implications

Novartis Cancer-Drug Patent Denied By India Supreme Court.  by Eva Von Schaper and Pratap Patnaik.  Bloomberg.  April 1, 2013.

Low-Cost Drugs In Poor Nations Get A Lift In Indian Court by Gardiner Harris and Katie Thomas.  The New York Times.  April 1, 2013.

Drug pricing is a source of dispute between the developed and developing world.  The price differences between patented drugs produced by large pharmaceutical companies and generic versions produced in developing countries can be tremendous.  As a result the ruling of the Indian Supreme Court that Novartis' leukemia drug Gleevec was not subject to patent protection under Indian law.

The two articles provide a political, medical, innovative, corporate, economic, competitive, human rights, and global context to the ruling.